Market Overview

ISI Group Downgrades Bruker To Neutral

Related BRKR
Bruker Corp Has 'Great Story,' But It's Not Time To Jump In Yet
Bruker Introduces MALDI Tissuetyper Solution With New High Speed RapifleX MALDI-TOF MS System For Anatomical Pathology Research
Bruker (BRKR) Frank H. Laukien on Q4 2015 Results - Earnings Call Transcript (Seeking Alpha)

Analysts at ISI Group downgraded Bruker (NASDAQ: BRKR) from “buy” to “neutral.”

Bruker shares have surged 44.61% over the past 52 weeks, while the S&P 500 index has gained 19.69% in the same period.

Bruker's shares fell 2.20% to close at $24.02 yesterday.

Latest Ratings for BRKR

Feb 2016Deutsche BankMaintainsHold
Jan 2016Cantor FitzgeraldUpgradesHoldBuy
Jan 2016Deutsche BankInitiates Coverage onHold

View More Analyst Ratings for BRKR
View the Latest Analyst Ratings

Posted-In: ISI GroupDowngrades Analyst Ratings


Related Articles (BRKR)

Get Benzinga's Newsletters